Brokerages Set Marker Therapeutics, Inc. (NASDAQ:MRKR) Price Target at $13.17

Marker Therapeutics, Inc. (NASDAQ:MRKR) has received an average rating of “Buy” from the five brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $13.1667.

Several brokerages recently issued reports on MRKR. Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a report on Saturday, September 27th. Wall Street Zen upgraded shares of Marker Therapeutics to a “sell” rating in a research note on Saturday, August 16th.

Institutional Trading of Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Jane Street Group LLC acquired a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 21,800 shares of the company’s stock, valued at approximately $33,000. Jane Street Group LLC owned approximately 0.19% of Marker Therapeutics as of its most recent filing with the Securities & Exchange Commission. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Trading Down 1.9%

Shares of MRKR opened at $1.06 on Friday. The firm has a market cap of $13.72 million, a P/E ratio of -0.77 and a beta of 1.47. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $5.95. The company’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.25.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.26. The firm had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.72 million. Marker Therapeutics had a negative net margin of 271.12% and a negative return on equity of 114.59%. Equities research analysts forecast that Marker Therapeutics will post -0.65 earnings per share for the current year.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.